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 ABSTRACT 
 
Objectives: Given the spread of multidrug-resistant tuberculosis (MDR-TB), new therapies are 
urgently needed, including the repurposing of existing drugs. We aimed to assess key 
considerations for the clinical and programmatic use of clofazimine (Cfz), a riminophenazine 
with anti-mycobacterial activity currently used to treat leprosy. 
 
Design: Fixed and random effects meta-analysis of cohort studies and systematic review 
 
Setting: Electronic and manual searches were combined. 
 
Inclusion criteria: Observational studies on treatment of multidrug- and extremely drug-
resistant tuberculosis with clofazimine or a clofazimine-containing regimen, and published 
guidance and documents relating to cost and availability were eligible. 
 
Results: Five observational studies enrolled 861 patients, of which 602 received Cfz. The pooled 
proportion of adverse drug reactions requiring discontinuation of Cfz treatment was 0.1% (95% 
CI: [0.0, 0.6%]), and the median frequency of all adverse events was 5.1%. Cfz showed in vitro 
efficacy against Mycobacterium tuberculosis, and Cfz-containing regimens may have had a 
useful role in the treatment of patients with drug-resistant strains and who had limited alternative 
treatment options. However, Cfz uptake remains insufficient to meet global needs; there is only 
one internationally quality-assured manufacturer, which produces a limited quantity of the drug 
prioritised for treatment of leprosy, the only indication for which the drug is registered. 
 
Conclusions: While the data were limited, Cfz was associated with a risk for adverse drug 
reactions comparable to that of first-line TB treatment, which could be reasonably managed 
under programmatic conditions. However, low market availability and high cost are important 
barriers to access to Cfz for MDR-TB patients. 
 
 
STRENGTHS AND LIMITATIONS OF THIS STUDY 
 
  We have reviewed a comprehensive body of peer-reviewed literature and policy guidance 
relating to the safety, use, cost, and availability of clofazimine in clinical practice. 
  This study shows that the burden of safety issues associated with Cfz use appears to be 
manageable by national TB programmes. The widespread use of Cfz is limited by low 
availability and relatively high cost. 
  Few studies were included in the meta-analysis since only a smaller number of studies have 
been conducted with clofazimine. Further research is needed. 
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1.  INTRODUCTION 
 
Drug-resistant strains of tuberculosis (TB) pose a serious obstacle to progress in global TB 
control.
1 In 2011, there were an estimated half a million new cases of multidrug-resistant 
tuberculosis (MDR-TB; resistance to, at least, rifampicin and isoniazid) worldwide.
2 Extensively 
drug-resistant (XDR-TB) cases, a form of MDR-TB with additional resistance to any 
fluoroquinolone and an injectable second-line drug, have been identified in 84 countries.
2,3 
Recent survey evidence from Belarus reported nearly one in two of all enrolled TB patients had 
MDR-TB, the highest proportion of MDR ever recorded.
4 
 
The recent approval of bedaquiline by the United States Food and Drug Administration (FDA), 
the first drug developed for TB treatment in nearly a half-century, and the filing of delamanid 
with the European Medicines Agency (EMA), are promising developments for treatment of 
TB.
5,6 However, the management of drug-resistant strains of Mycobacterium tuberculosis (M.tb) 
necessitates new effective treatment regimens, composed of at least four effective drugs. In light 
of the limited treatment options available for patients affected by severe patterns of drug-
resistant TB, some have recommended repurposing older drugs, though there are significant 
concerns with the adverse drug reaction (ADR) profiles and long term safety of several agents, 
and conflicting evidence of their efficacy.
7,8 One potential candidate to be repurposed is 
clofazimine (Cfz), a riminophenazine derived from a R-substitution at the imino group.
9 Cfz has 
apparent anti-mycobacterial and anti-inflammatory activity, though its precise mechanism of 
action is still unclear.
10 The drug is known to be highly lipophilic, accumulating in fatty tissues 
with uptake by human mononuclear phagocytes, the same cells infected by M. tb.
11 Cfz also 
appears to exhibit a property uniquely relevant for tuberculosis treatment: despite its long half-
life and accumulation in tissue, the risk of developing resistance is relatively low.
12 
 
Although Cfz was originally developed for the treatment of tuberculosis, its current medical 
indication is for the treatment of multi- and paucibacillary leprosy, including severe erythema 
nodosum leprosum reactions in leprosy patients.
13 While in vitro studies suggested high anti-TB 
activity, poor in vivo results in the mid-1950s led to the abandonment of clinical development as 
an anti-tuberculosis agent.
14,15 In the past decade, there has been renewed and growing interest in 
the use of Cfz as an anti-TB agent. An MDR-TB treatment observational study conducted in 
Bangladesh showed favourable outcomes, even with a significantly shorter treatment duration 
than the current WHO recommended regimen.
16 A multi-country randomised control trial to 
evaluate a standardised nine-month regimen containing Cfz for the treatment of MDR-TB is 
currently under way, and observational cohort studies are being conducted in some West African 
countries.
17 Given the growing evidence supporting the use of Cfz in the treatment of patients 
with MDR- and XDR-TB treatment, we sought to assess the key considerations, including safety, 
effectiveness, management, and cost, in relation to the programmatic and clinical use of Cfz by 
national TB programmes (NTP).  
 
 
 
 
 
 Clofazimine Paper – BMJ Open | 11 November 2013 | Page 4 
2. METHODS 
 
Study Design and Data Sources 
 
Our meta-analysis and systematic review were conducted using a prospective protocol according 
to MOOSE (Meta-analysis of Observational Studies in Epidemiology) and PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-analyses) guidelines for reporting systematic 
reviews of observational study results (Supplementary Material online).
18,19 Studies published 
between 1950 and May 2013 were identified from an electronic search of the PubMed, 
MEDLINE, Embase, and Cochrane Library databases. The key words and Medical Subject 
Heading terms included: ‗clofazimine‘, ‗B663‘, Lamprene‘, ‗tuberculosis‘, ‗side effects‘, 
‗adverse events‘, ‗adverse drug reactions‘, ‗sequella‘, ‗toxicity‘, ‗tolerability‘, ‗outcomes‘, 
‗treatment‘, ‗effectiveness‘, ‗efficacy‘, ‗cure‘, ‗success‘, ‗guideline‘, ‗treatment‘, or ‗safety‘. We 
contacted researchers and manually collected references of all retrieved articles, selected review 
articles, clinical trial registration notices, and conference abstracts, as needed. These additional 
studies were merged with our search results, following exclusion of non-relevant or duplicate 
citations. Policy guidelines and drug label information were retrieved from manual searches of 
World Health Organization publications, as well as those of two stringent regulatory agencies, 
the US FDA and EMA. 
 
Outcome Variables and Data Extraction 
 
The primary aims of our study was to perform a meta-analysis of the safety of Cfz from 
published studies and a systematic analysis of the effectiveness, management, and cost of Cfz 
from the peer-reviewed literature as well as published guidance.  
 
For our safety analysis, our primary outcomes of interest were adverse events and adverse drug 
reactions (ADR). We defined an adverse drug reaction (ADR) as an appreciably harmful or 
unpleasant reaction caused by a drug that is serious enough to warrant the discontinuation or 
revision of treatment.
20 In contrast, an adverse event included any undesirable reactions reported 
by patients or clinicians, including mild reactions that had no bearing on treatment. Since the use 
of the term ―adverse event‖ and ―serious adverse events‖ was inconsistent in the reviewed 
studies and the criteria for judging an adverse event as serious were not consistently reported, we 
used ADR as a measure of Cfz‘s safety profile. Using methods described previously,
21 we used 
challenge-dechallenge to evaluate ADR data: a reaction was attributed solely to Cfz if 
discontinuation of the drug or reducing the dose led to reported disappearance of the toxicity.
22 
Prevalence (%) was measured as a proportion relative to the total number of drug-receiving 
patients. 
 
Data on study characteristics, methodological quality, and results were independently extracted 
from each selected article using a pre-defined extraction form by two authors (TJH and SD). This 
form captured: author, study location, study design, observation period, number of patients 
treated, patient age, sex and reported race or ethnicity, drug resistance profile, prior treatment 
with second-line drugs, HIV status, treatment regimen with Cfz, dosage, duration of treatment, 
treatment outcomes, reported ADRs by agent and rate of discontinuation. An additional author 
(DFW) independently assessed the validity of included citations and extracted data. Clofazimine Paper – BMJ Open | 11 November 2013 | Page 5 
 
Statistical Analysis 
 
We calculated point estimates and 95% confidence intervals (CI) for the frequency of adverse 
events and ADRs. We assessed the heterogeneity between studies using the I
2 statistic, which 
reports the proportion of total variance across studies that is due to between-study heterogeneity 
rather than by randomness (Appendix). Based on this assessment, we used the DerSimonian and 
Laird random effects model for pooling estimates and calculating 95% CI of adverse event 
frequencies, and the inverse-variance weighted fixed effects model for ADRs.
 23 
24 Since some 
studies reported no ADRs, we also performed a post hoc sensitivity analysis to calculate 95% CI 
of adverse events and ADRs using the Wilson score method and found that the intervals did not 
differ significantly. We defined statistical significance at the P < 0.05 level. Forest plots illustrate 
the distributions of pooling adverse event data by various stratification criteria. Statistical 
analyses were performed using Stata (version 12.0, Stata Corp.).  
 
3. RESULTS 
 
Safety 
 
From 1,248 citations identified by our search strategy, 147 were selected for full-text review 
(Figure 1). A total of five studies were subsequently included in the review for safety. 
 
The characteristics of the five selected studies with safety data are summarised in Table 
1.
16,25,26,27,28 Of the total 861 participants, 602 patients received Cfz as part of their TB treatment 
regimens. The study periods ranged from 1993 to 2012. The average study population was 144 
patients (range: 10-427). The daily dose range of Cfz administered in clinical settings was 50-
100 mg, though one study reported a daily dose of 300 mg.
25 Drug resistance patterns, duration 
and extent of prior TB treatment, HIV status, and types of ADRs were variably reported.  
 
The two most reported adverse event categories were dermal (skin discoloration) and 
gastrointestinal. As shown in Figure 2, the overall pooled proportion of all adverse events 
attributed to Cfz was 21.9% (95% CI: [0.0, 46.1%]), though the median frequency of adverse 
events was 5·1%. The pooled proportion was disproportionately affected by an outlier reporting 
adverse events in 88·6% (95% CI: [75.4, 96.2%]) of cases.
27 
 
Not all reported adverse events required discontinuation of Cfz treatment. From our fixed effects 
model, the pooled proportion of ADRs requiring discontinuation or withdrawal of Cfz was 0.1% 
(95% CI: [0.0, 0.6%]), with the frequency of ADRs ranging from 0% (95% CI: [0.0, 1.1%]) to 
11·8% (95% CI: [2.0, 35.6%]). 
 
Efficacy 
 
Early in vitro studies of Cfz reported positive bactericidal efficacy of Cfz.
29,30,31,32,33 More recent 
in vitro and in vivo evidence suggests that Cfz also has sustained sterilizing activity against latent 
or persistent bacterial populations of M. tuberculosis.
34 Currently novel analogues of Cfz are Clofazimine Paper – BMJ Open | 11 November 2013 | Page 6 
under investigation with comparable efficacy but shorter half-lives, potentially reducing tissue 
accumulation and resulting skin pigmentation.
35  
 
In vivo studies in mice and hamsters reported significant activity of Cfz, though accumulation in 
animal tissues may lead to overestimation of drug activity when subsequently plated on solid 
media.
12,30,36,37,38 Earlier studies had showed that Cfz had little or no activity in guinea pig and 
monkey models.
39,40 It was later thought that these poor in vivo results and monotherapy-induced 
resistance in guinea pigs and monkeys may have been a result of low absorption of the drug by 
the oral route.
29 Recently, Cfz combined with bedaquiline and pyrazinamide has been shown to 
be superior to the current first-line regimen in reducing colony-forming unit counts at one month 
in mice.
41Cfz combined with the standard second-line regimen also significantly improved 
culture conversion and relapse prevention, compared with a regimen without Cfz, in mice.
42 In 
addition, the sterilizing activity of bedaquiline and pyrazinamide was significantly improved 
with the addition of Cfz.
43  
 
Effectiveness 
 
In a recent systematic review and meta-analysis of 3,489 patients treated for drug resistant TB 
across 10 countries, Dey et al. reported a pooled treatment success rate of 62.0% (95% CI: [52.8–
71.1%]) from treatment regimens containing Cfz, with success defined as cure and/or treatment 
completion.
44 The success rate in HIV/MDR-TB co-infected patients was not significantly 
different from the overall success rate. In another systematic review of patients treated with Cfz-
containing regimens, Gupta et al. found no significant differences in the proportions with 
favourable outcomes between MDR- (65%; 95% CI: [52-79%]) and XDR-TB patients (66%; 
95% CI: [42-89%]).
45 There was substantial variation in estimates of mortality during treatment 
with Cfz-containing regimens, ranging from 1.0% (95% CI: 0.1%–2.6%) to 63.4% (95% CI: 
38.3%–85.0%), though the risk of death attributed solely to Cfz, after adjusting for covariates, 
was not reported. Further cohort studies showing a favourable effect of Cfz-containing regimens 
have been reported in Benin,
46 South Africa,
47 and Ukraine,
48 though limited benefit from Cfz 
was found in studies in Brazil
49 and Sri Lanka
50. 
 
Two clinical trials are currently ongoing involving the investigation of the efficacy and safety of 
treatment regimens containing Cfz (Table 2). The Global Alliance for TB Drug Development is 
conducting a Phase 2 study to evaluate the early bactericidal activity of Cfz (dosed at 300 mg for 
the first two days and 100 mg thereafter) combined with bedaquiline and pyrazinamide, 
compared with first-line treatment.
51 The Phase 3 STREAM trial, sponsored by the International 
Union Against Tuberculosis and Lung Disease, is comparing a modified MDR-TB treatment 
regimen, based on the shorter treatment regimens assessed in Bangladesh,
16 with regimens based 
on the current WHO guidelines for MDR-TB treatment. The STREAM trial involves sites in 
Ethiopia, India, South Africa and Viet Nam.
17 Follow up is expected for all patients in the study 
for 27-33 months, with final results anticipated after October 2016. 
 
Availability, Cost and Demand Forecast 
 
Cfz was registered under the trade name Lamprene™ by Novartis in the U.S. in 1986.
52 Quality-
assured Cfz is available on very limited quantities for the treatment of MDR-TB patients on a Clofazimine Paper – BMJ Open | 11 November 2013 | Page 7 
patient-named basis through the Global Drug Facility (GDF) mechanism of the Stop TB 
Partnership, which uses a distributor authorised by Novartis.
53,54,55 Securing a steady supply of 
quality-assured Cfz that can meet the increasing demand for MDR-TB treatment, without 
jeopardizing the needs of the global programme for leprosy elimination, is currently a major 
challenge in the response to MDR-TB.
56 
 
The price of the 100mg product through the GDF mechanism is US$120.86 per hundred 
capsules, or roughly US$1.21 per one capsule. The cost of a daily dosage of Cfz varies between 
US$1.21 (when a 100mg dosage is used) and US$3.63 (when 300 mg are used). Depending on 
the regimen and dosage, the cost of Cfz can be higher than the cost of a daily dosage of most 
injectables used in the treatment of intensive phase of MDR-TB treatment. By our calculations, 
the estimated annual cost of procuring a 24 month-regimen of Cfz will range between $2-$20 
million, depending on the number of patients (low estimate: XDR-TB patients only; high 
estimate: all MDR-TB patients) treated. 
 
Global policy, guidelines, and national practices 
 
From a search of national, regional, and international guidelines and regulations relating to the 
use of Cfz, two policy sources were retrieved from the World Health Organization
57,58,59,60 and 
the U.S. Food and Drug Administration (FDA)
61 (Table 3). 
 
Cfz is currently indicated solely for leprosy by the WHO and the US FDA, and is included in the 
WHO Model Lists of Essential Medicines for adults and children.
62,63 For this use, the drug is 
provided free to endemic countries through an agreement with the sole manufacturer of quality-
assured Cfz, Novartis, first signed in 1999 and renewed in 2010.
64 The most recent donation, 
valued at US$26 million, will treat an estimated 1.1 million patients with leprosy over five years 
(2010-2015). In the U.S., Cfz can only be obtained through the National Hansen‘s Disease 
Program under a single-patient treatment investigational new drug protocol administered by the 
US FDA.
65 
 
WHO guidelines currently do not recommend the routine use of Cfz for the treatment of DR-TB, 
due to insufficient data supporting the drug‘s efficacy and long term safety.
57,58 A WHO 
consultation in early 2012 on diagnostic definition and treatment options for so-called ―totally 
drug-resistant TB‖ concluded, based on expert opinion, that Cfz (at a daily dose of 100mg) and 
linezolid were likely to be the most effective in the Group 5 category of second-line anti-TB 
drugs for the treatment of XDR-TB.
66  
 
Seven articles were identified from the literature on the national policies, guidelines and 
practices on the use of Cfz to treat MDR-TB.
67,68, 70,71,72,73,74 There has been virtually no 
published evidence of the use of Cfz in the Russian Federation. The two articles retrieved from 
the Russian-language literature mention solely that Cfz is included in international guidelines as 
a third-line therapy but note that the drug is not currently registered in the country.
67,68 Cfz was 
previously registered with the Russian Ministry of Health for the indication of leprosy in 1977 
and re-registered in 1989. In 1995, Cfz‘s registration was annulled for unknown reasons and was 
not identifiable through the State Registry of Medical Substances as of May 2013.
69 
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In India, use of Cfz has been associated with varying degrees of success in a number of settings, 
including in TB cases with strains described as so-called ―totally drug-resistant.‖
70 A survey of 
the clinical practices in the management of DR-TB cases by chest physicians in the Indian state 
of Maharashtra found that Cfz was a preferred drug, being included in the treatment regimens by 
15 respondents out of the 29 surveyed.
71 A number of studies have reported the use of aggressive 
supervised therapies, including Cfz and other Group 5 drugs such as linezolid and 
clarithromycin.
72,73 In one such study with 14 patients with XDR-TB, only two cases achieved 
complete cure (defined to be at least five negative culture results for the final 12 months of 
treatment), compared with four deaths.
74 
 
4. DISCUSSION 
 
While data were limited, this study has shown a low proportion of adverse events requiring 
discontinuation of treatment attributed to Cfz at doses ranging from 50-300mg daily. Our pooled 
frequency of Cfz ADRs at 0.1% is comparable to the incidence of serious ADRs reported with 
first-line TB treatment.
75  
 
These findings are in line with those made in an unpublished report on spontaneous individual 
case safety reports (ICSR) submitted between 1976 and 2012 to the WHO‘s International Drug 
Monitoring Programme, which found that Cfz was associated with 288 ICSRs accounting for 
674 ADRs (Wang S et al., unpublished data). The three most frequent systemic categories 
involved in the TB-specific ADRs were central and peripheral nervous system (23.2%), 
gastrointestinal (17.9%), and skin (16.1%). 
 
Our review of preclinical studies of Cfz suggests that this drug has sterilizing activity against 
M.tb. Observational cohort studies in Bangladesh, Benin, China, Niger, Peru, and Sri Lanka, 
among other settings, show an association between treatment regimens containing Cfz and 
favourable outcomes, including shortened treatment duration, and add support to its inclusion by 
WHO in the Group 5 of drugs to be considered in the management of MDR-TB.
58 A high 
variance in mortality rates of patients receiving Cfz-containing drug combinations is observed in 
some studies. While these data might be confounded by indication— as patients who receive 
Cfz-containing regimens tend to be those with broader-spectrum drug resistance patterns and 
more advanced disease — the increasing use of Cfz should be coupled with strengthening of 
active pharmacovigilance systems.
22 Results from the Phase 3 STREAM and Phase 2 Global TB 
Alliance trials will help to elucidate further the long-term safety and effectiveness of Cfz in the 
treatment of MDR-TB.  
 
Our analysis is limited by the small number of available studies and published materials on Cfz. 
As ADRs are often rare, the paucity of clinical investigations with Cfz in the treatment of TB 
means that our results should be interpreted with some caution. While we attempted to categorise 
ADRs based on resolution after withdrawal or recurrence with re-challenge, reporting varied 
across studies, and different thresholds may have been applied to report adverse events and 
ADRs. In the Xu et al. study, for instance, 39 out of 44 (87%) patients were reported to have 
experienced adverse events after starting Cfz.
27 This high level of adverse events could be 
attributed to the high frequency of reported skin discolouration (36 patients), a known reaction to 
Cfz treatment, but only two patients discontinued Cfz altogether. There were also insufficient Clofazimine Paper – BMJ Open | 11 November 2013 | Page 9 
data on extent of prior treatment, drug susceptibility, and HIV status—factors that could result in 
varying severity of disease.  Another limitation was that we considered participants in our meta-
analysis as those with at least one ADR while being treated with Cfz, rather than cumulatively 
counting multiple ADRs that may have been experienced. In addition, to review the global 
landscape of policies and regulatory actions relating to Cfz, we relied on databases, search 
engines, and manual searches which are biased in favour of English-language publications. Many 
more national and local policies may exist that were not captured by this paper. 
 
The use of Cfz in the clinical settings where MDR-TB patients are treated has been increasing 
over the last two decades. The progress countries are making towards universal access to 
diagnosis and treatment of MDR-TB
76 is resulting in sustained and increasing demand for this 
product, at least until more new and effective drugs are available. The GDF‘s projected forecast 
based on the ongoing global scale up of MDR-TB management suggests that the current quality-
assured supply line is insufficient to meet this demand. GDF and the Global Fund regularly 
publish joint invitations to manufacturers of first, second and third-line anti-tuberculosis 
medicines to submit an Expression of Interest for TB drug products evaluation by the Expert 
Review Panel. However, to date, no successful review of clofazimine has been reported through 
this mechanism. To improve access to the drug, generic manufacturers that can complement 
Novartis‘ production capacity should be identified. The inclusion of more manufacturers in the 
market may also contribute to a reduction in the cost of the drug, further improving access.  
 
Despite these limitations, this paper underscores the potential value of Cfz‘s inclusion in the 
treatment regimens for MDR- and XDR-TB cases. However, even if the ongoing clinical trials 
and observational studies confirm the earlier findings reviewed here, much more will need to be 
done to make Cfz both available and affordable.   Clofazimine Paper – BMJ Open | 11 November 2013 | Page 10 
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Figure 1 Study selection process for meta-analysis of safety of Cfz in treatment of TB 
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Table 1 Characteristics of studies included in a systematic review of safety of clofazimine in the treatment of TB 
 
Author, year, reference  Country  Study period  Study design 
Study population 
N. included subjects 
Treatment 
duration (mo.)  Regimen 
N. given  
Cfz 
Daily Cfz 
dose (mg) 
                 
Goble et al., 1993
25  USA  1973-1983  Retrospective  171 patients included 
   Age: 46 (17-79) 
   DS: 0; DR: 98 
7  Individualised  17  300 
Geerligs et al., 2000
26  Netherlands  1985-1998  Retrospective  44 patients included 
   Age: 33 (10-82) 
   DS: 0; DR: 44 
20-53  Individualised  39  Not stated. 
Van Deun et al., 2010
16  Bangladesh  1997-2007  Prospective  427 patients included 
   Age: 33.8 (mean) 
   DS: 0; DR: 427 
3-15  Cfz, Km, Ofx, 
E, H, Z, Pto 
427  50-100 
Xu et al., 2012
27  China, PR  2006-2011  Retrospective  144 patients included 
   Age: 38.8 ± 10.8 (Cfz);  
    47.4 ± 11.8 (non-Cfz) 
   DS: 0; DR: 144 
2.2 ± 1.7 (Cfz); 
2.1 ± 1.3 (non-
Cfz)  
Individualised  44  100 
Piubello et al., 2012
28  Niger  2008-2010  Retrospective  65 patients included 
   Age: 32.7 (16-66) 
   DS: 0; DR: 65 
12   Cfz, Km, Ga, 
E, H, Z, Pth 
65  50-100 
                 
 
DS = drug-sensitive; DR = drug-resistant (to at least two agents in standard-line therapy). Cfz = clofazimine; H = isoniazid; E = ethambutol; Z = pyrazinamide; S = streptomycin; Et = ethionamide; Km = kanamycin; Ofx = 
ofloxacin; Ga = gatifloxacin; Pto = prothionamide. 
 
 
Table 2 Current preclinical and clinical development of Cfz for TB indications 
 
Phase  Date  Trial name (identifier)  Sponsor  Design  Treatment arms (Cfz daily dose)  Primary endpoint 
               
Phase III  2011-2016  STREAM 
(ISRCTN78372190)
17 
International Union 
Against Tuberculosis and 
Lung Disease 
Non-inferiority  Bangladesh regimen
16 vs. locally used 
WHO MDR-TB regimen 
(Cfz = 50-100 mg) 
Proportion of patients with a 
favourable outcome (cure or 
completion) 27 months after 
randomisation 
Phase II  2012-2013  NC-003 
(NCT01691534)
51 
Global Alliance for TB 
Drug Development 
Superiority  Bedaquiline (J), PA-824 (PA), Z, Cfz 
vs. J-PA-Z vs. J-PA-Cfz vs. J-Z-Cfz vs. 
Z alone vs. Cfz alone vs. Rifafour 
(Cfz = 100-300 mg) 
Early bactericidal activity 
(rate of change of log CFU 
per ml sputum) 
               
 Clofazimine Paper – BMJ Open | 11 November 2013 | Page 13 
Table 3 Guidelines and labelling regulations for clofazimine 
 
Authority  Region  Indication  Adverse effects  Off-label use  Recommendation for Cfz in TB use 
             
World Health 
Organization
57,58 
Global  MDR- and XDR-TB  Gastrointestinal intolerance  Named patient 
basis on 
―exceptional‖ 
grounds 
2011: ―May be used but not included among 
drugs making up the standard regimen‖ 
2008: ―Only if additional drugs are needed to 
bring the total to four‖ 
World Health 
Organization
59,60 
Global  Leprosy and severe erythema 
nodosum leprosum (ENL) reactions in 
leprosy 
Discoloration, ichthyosis  Named patient 
basis on 
―exceptional‖ 
grounds 
―…In the treatment of multi-drug resistant 
tuberculosis (MDR TB)…WHO has found no 
evidence of its effectiveness for these forms of 
treatment‖
59 
Food and Drug 
Administration
61 
USA  Lepromatous leprosy, including 
dapsone-resistant lepromatous leprosy 
and lepromatous leprosy complicated 
by ENL 
Skin pigmentation, 
gastrointestinal, conjunctival 
and corneal pigmentation, 
discoloration of urine, feces, 
sputum, and sweat 
Single-patient 
treatment 
investigational 
new drug protocol 
  
Not stated. 
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Figure 2 Forest plot of all reported adverse events associated with or ADRs attributed to clofazimine and 
clofazimine-containing regimens 
 
Pooled estimates using inverse-variance weighted fixed effects (F-E) and random effects (R-E) models are shown. The random effects model was 
used for adverse events estimates (I
2=98.7%; P<0.001) and fixed effects for ADRs (I
2=11.5%; P=0.34). 
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